Overview
At the New York Lung Cancers Symposium® attendees will experience a comprehensive overview of multidisciplinary lung cancer treatment. Now in it’s 20th year, this meeting is designed to increase your knowledge of lung cancer therapy, including the roles that surgery, radiology, pulmonology, and pathology play to ensure the most accurate diagnosis of lung cancers. You will hear thought leaders from the New York area discuss optimal approaches for early-stage and locally advanced disease, as well as present the latest data on immunotherapy and targeted agents in metastatic lung cancers. These multidisciplinary interactions will be illustrated in a tumor board format, which will also allow participants to present questions and clinical challenges from their practice.
The ever-popular interactive case challenges will provide you with an opportunity to discuss the application of clinical data for real-world patient cases. A special session has been designed for nurse practitioners and physician assistants, to provide a tailored experience for learning and networking.
Upon completion of this activity, learners will be better able to:
- Evaluate emerging therapeutic targets and new biomarker testing strategies to guide precision medicine approaches for patients with lung cancers
- Assess recent efficacy and safety data from pivotal clinical trials investigating novel therapies and combination approaches for the treatment of localized and metastatic lung cancers
- Apply the latest data, guideline recommendations, and disease/patient-specific factors to optimize precision treatment approaches for patients with localized and metastatic lung cancers
- Develop evidence-based strategies to mitigate treatment-related adverse effects associated with novel therapies and combination approaches for the treatment of lung cancers
Upon completion of this activity, learners will be better able to:
- Evaluate emerging therapeutic targets and new biomarker testing strategies to guide precision medicine approaches for patients with lung cancers
- Assess recent efficacy and safety data from pivotal clinical trials investigating novel therapies and combination approaches for the treatment of localized and metastatic lung cancers
- Apply the latest data, guideline recommendations, and disease/patient-specific factors to optimize precision treatment approaches for patients with localized and metastatic lung cancers
- Develop evidence-based strategies to mitigate treatment-related adverse effects associated with novel therapies and combination approaches for the treatment of lung cancers